Skip to main content
SpringerLink
Log in

Clinical Implications of MicroRNAs in AML

  • Chapter
  • First Online:
Targeted Therapy of Acute Myeloid Leukemia

Part of the book series: Current Cancer Research ((CUCR))

Abstract

It is now established that deregulated microRNA (miRNA) expression is a prominent feature in acute myeloid leukemia (AML). Subsequently, functional studies have shown that miRNAs play an important role in the pathogenesis of AML by acting as tumor suppressors or oncogenes. Recent data indicate that distinctive miRNA expression signatures are associated with chemotherapy response and clinical outcome and that targeting miRNAs in AML is a novel emerging therapeutic strategy. In this chapter, we will discuss the clinical application of miRNAs as biomarkers for diagnosis and prognosis in AML and review the current strategies to target miRNAs in this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

    Article  CAS  PubMed  Google Scholar 

  • Blum W, Garzon R et al (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 107:7473–7478

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Blum W, Schwind S et al (2012) Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 119:6025–6031

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866

    Article  CAS  PubMed  Google Scholar 

  • Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10:704–714

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Dixon-McIver A, East P et al (2008) Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 3:e2141

    Article  PubMed Central  PubMed  Google Scholar 

  • Ebert MS, Neilson JR et al (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4:721–726

    Article  CAS  PubMed  Google Scholar 

  • Elmen J, Lindow M et al (2008a) LNA-mediated microRNA silencing in non-human primates. Nature 452:896–899

    Google Scholar 

  • Elmen J, Lindow M et al (2008b) Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36:1153–1162

    Google Scholar 

  • Garzon R, Croce CM (2008a) MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 15:352–358

    Google Scholar 

  • Garzon R, Volinia S et al (2008b) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111:3183–3189

    Google Scholar 

  • Garzon R, Liu S et al (2009) MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113:6411–6418

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Garzon R, Marcucci G et al (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9:775–789

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Gumireddy K, Young DD et al (2008) Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 47:7482–7484

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kota J, Chivukula RR et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005–1017

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Krutzfeldt J, Rajewsky N et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:685–689

    Article  PubMed  Google Scholar 

  • Lee Y, Kim M et al (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051–4060

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Liu S, Wu LC et al (2010) Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17:333–347

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Marcucci G, Mrozek K et al (2011) The prognostic and functional role of microRNAs in AML. Blood 117:1121–1219

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Marcucci G, Radmacher MD et al (2008) MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1919–1928

    Article  CAS  PubMed  Google Scholar 

  • Sandhu S, Garzon R (2011) Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol 38:781–787

    Article  CAS  PubMed  Google Scholar 

  • Schwind S, Maharry K et al (2010) Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28:5257–5264

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Stenvang J, Petri A et al (2012) Inhibition of microRNA function by antimiR oligonucleotides. Silence 3:2–17

    Article  Google Scholar 

  • Young DD, Connely CM et al (2010) Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc 132:7976–7981

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Medicine, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, 460 W 12th Avenue, 43210, Columbus, OH, USA

    Parvathi Ranganathan Ph.D. & Ramiro Garzon M.D.

Authors
  1. Parvathi Ranganathan Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramiro Garzon M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramiro Garzon M.D. .

Editor information

Editors and Affiliations

  1. Dept. Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

    Michael Andreeff

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag New York

About this chapter

Cite this chapter

Ranganathan, P., Garzon, R. (2015). Clinical Implications of MicroRNAs in AML. In: Andreeff, M. (eds) Targeted Therapy of Acute Myeloid Leukemia. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1393-0_37

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1393-0_37

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1392-3

  • Online ISBN: 978-1-4939-1393-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation